Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed ...

As the commercial momentum behind Lilly’s tirzepatide franchise continues, analysts are increasingly turning their attention ...

Even as AbbVie has demonstrated that Rinvoq and Skyrizi sales can more than make up for Humira's tumble over the patent cliff ...

Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial ...

Roughly one year into launch, Lenz Therapeutics, the maker of Vizz eye drops fo | In a massive overhaul of its operating ...

Amid a push to win back investor confidence in its R&D trajectory, Sanofi still has significant commercial powder to burn with Dupixent, as illustrated in a third-quarter showing that looked strong by ...

Next-generation antibody-drug conjugates, bispecifics, radiopharmaceuticals, tyrosine kinase inhibitors ... Fierce provides a ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia ...

Things have been relatively quiet on the layoff front for the company in 2026, although it was widely reported in June that ...